重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症的安全性问题  

Safety of Recombinant Human Growth Hormone in Treating Children with Growth Hormone Deficiency and Idiopathic Short Stature

作　　者：舒畅[1] 潘慧[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科,北京100730

出　　处：《中国医学科学院学报》2011年第2期123-126,共4页Acta Academiae Medicinae Sinicae

摘　　要：重组人生长激素的安全性总体较好,但也有少量不良反应出现,如水钠潴留、良性颅内高压、胰岛素敏感性下降、继发肿瘤发生的危险性升高、脊柱侧凸、股骨头滑脱等,但总体发生率较低。Recombinant human growth hormone is generally safe in treating children with growth hormone deficiency and idiopathic short stature.However,side effects such as sodium and water retention,benign intracranial hypertension,insulin insensitivity,increasing risk of secondary neoplasm,scoliosis,and slipped capital femoral epiphysis may occur occasionally,although the overall incidence remains low.

关 键 词：重组人生长激素 生长激素缺乏症 特发性矮小 不良反应 

分 类 号：R584.21[医药卫生—内分泌]